The CSB protein (ERCC6) is a SWI/SNF-like ATPase involved in maintaining chromatin structure and resolving transcription-associated DNA damage . Mutations in the CSB gene cause Cockayne syndrome (CS), a rare genetic disorder characterized by premature aging, neurodegeneration, and cancer susceptibility .
CSB antibodies are categorized into polyclonal and monoclonal variants, each with distinct advantages:
Polyclonal antibodies (e.g., GTX104589) offer broad epitope recognition but may have higher background noise .
Recombinant monoclonal antibodies (VeRSaMAb) are engineered for specificity and reproducibility, eliminating lot-to-lot variability .
CSB antibodies are critical tools in studying DNA repair, chromatin dynamics, and neurodegenerative diseases.
Detects CSB protein in nuclear extracts (e.g., 1:1000 dilution for GTX104589) .
Validates CSB knockdown in cellular models (e.g., siERCC6-treated cells) .
Identifies CSB interactions with BRCA1, MRN complex, and CtIP .
Confirms strand-annealing activity in CSB immunodepletion assays .
CSB facilitates repair of oxidative DNA lesions (8-oxoguanine) via BER pathways .
Promotes resolution of DNA interstrand crosslinks (ICLs) by coordinating with SNM1A .
CSB knockdown leads to mitochondrial dysfunction, including reduced POLG1 levels and increased protease activity (HTRA2/3) .
Stimulates TOP2A/B activity to prevent R-loop/DSB accumulation .
Interacts with BRCA1 in late S/G2 phase to regulate MRN-CtIP-mediated repair .
| Antibody | Dilution | Application | Sensitivity | Background |
|---|---|---|---|---|
| GTX104589 | 1:1000 (WB) | CSB detection | High | Moderate |
| ab96089 | 1:500 (WB) | CSB validation | Moderate | Low |
| VeRSaMAb | 1:200 (IF) | R-loop analysis | Very High | Minimal |